What's The Big-Up-Front Deal? Biopharma Up-Fronts Hit A High
Biopharma companies paid an average of $82 million up front when in-licensing assets over the past three years, but in some cases they shelled out much more. The number of deals with big up-fronts has doubled since 2013, and 2015 is on track to exceed last year's value.
Register for our free email digests: